Monograph
A03BA03 - Hyoscyamine |
Propably not porphyrinogenic |
PNP |
Rationale
Hoyscyamine is not metabolized by, nor is it reported to have any influence on the activity of any of the cytochrome P450 enzymes. Hyoscyamine shows no pharmacokinetic or pharmacodynamic effects that could point to porphyrinogenicity.
Chemical description
Antimuscarinic tertiary amine alkaloid, levo-isomer to atropine.
Therapeutic characteristics
Hyoscyamine is an anticholinergic used in the symptomatic reliev of gastrointestinal disorders. It is administered orally, often as a depot formulation.
Confounding side effect: constipation.
Metabolism and pharmacokinetics
Hyoscyamine is not metabolized by CYP enzymes.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Drug reference publications | |
| 1. | DrugBank. hyoscyamine.
|
|
| 2. | McEvoy GK, editor. hyoscyamine. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (30.03.2012).
|
|
| 3. | Sweetman SC, editor. Martindale: The complete drug reference. Hyoscyamine. Pharmaceutical Press 2009.
|
|
| * | Summary of Product Characteristics | |
| 4. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Egazil.
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Hyoscyamine
© NAPOS 2025